All In Biotech

Drug Trial Radar · NCT04246047

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 494 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

494

Actual

Start

May 7, 2020

Primary completion

Oct 2, 2023

Study completion Oct 8, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • Belantamab mafodotinDrug

    Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

  • DaratumumabDrug

    Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody

  • BortezomibDrug

    Proteasome Inhibitor

  • DexamethasoneDrug

    Synthetic glucocorticoid with anti-tumor activity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to approximately 41 months

Locations

143 sites in 20 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Yuma, Arizona

  • GSK Investigational Site

    Mission, Kansas

  • GSK Investigational Site

    Denver, North Carolina

  • GSK Investigational Site

    Blue Ash, Ohio

  • GSK Investigational Site

    Tyler, Texas

  • GSK Investigational Site

    Roanoke, Virginia

  • GSK Investigational Site

    Camperdown, New South Wales, Australia

  • GSK Investigational Site

    Liverpool, New South Wales, Australia

  • GSK Investigational Site

    Newcastle, New South Wales, Australia

  • GSK Investigational Site

    St Leonards, New South Wales, Australia

  • GSK Investigational Site

    Wollongong, New South Wales, Australia

  • GSK Investigational Site

    Benowa, Queensland, Australia

  • GSK Investigational Site

    Herston, Queensland, Australia

  • GSK Investigational Site

    Ashford, South Australia, Australia

  • GSK Investigational Site

    Box Hill, Victoria, Australia

  • GSK Investigational Site

    Heidelberg, Victoria, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Murdoch, Western Australia, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Roeselare, Belgium

  • GSK Investigational Site

    Jette, Brussels Capital, Belgium

  • GSK Investigational Site

    Woluwé-Saint-Lambert, Brussels Capital, Belgium

  • GSK Investigational Site

    Ghent, Oost-Vlaanderen, Belgium

  • GSK Investigational Site

    Joinville, Brazil

  • GSK Investigational Site

    Natal, Brazil

  • GSK Investigational Site

    Rio de Janeiro, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Florianópolis, Santa Catarina, Brazil

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    London, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Changchun, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Hangzhou, China

Showing 40 of 143 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.